Breaking News Instant updates and real-time market news.

NEO

NeoGenomics

$8.32

0.02 (0.24%)

, AET

Aetna

$172.06

-1.85 (-1.06%)

07:03
03/20/18
03/20
07:03
03/20/18
07:03

NeoGenomics names Sharon Virag CFO

NeoGenomics (AET) announced the appointment of George Cardoza as president of the Pharma Services Division and Sharon Virag as CFO. Virag will succeed George Cardoza, who has served as CFO since 2009. Her appointment is effective on March 27, 2018. Sharon Virag was formerly VP, corporate finance and chief accounting officer, at Aetna (AET). George Cardoza's appointment as president of the Pharma Services Division is a newly created position. In 4Q17, the Pharma Services Division reported revenue growth of 69% to $8.7M with a record number of new contracts signed. The Division is adding resources and capacity, including a new Lab in Rolle Switzerland, to meet the growing demand for its services.

NEO

NeoGenomics

$8.32

0.02 (0.24%)

AET

Aetna

$172.06

-1.85 (-1.06%)

  • 16

    Apr

  • 29

    May

  • 30

    May

NEO NeoGenomics
$8.32

0.02 (0.24%)

04/26/17
CANT
04/26/17
NO CHANGE
Target $11
CANT
Overweight
NeoGenomics shares 'oversold' on lowered 2017 guidance, says Cantor
Cantor analyst Bryan Brokmeier reiterates an Overweight rating and a $11 price target on NeoGenomics following mixed Q1 results. The analyst notes that the stock is down after the company revised its 2017 outlook, but he believes shares are oversold. NeoGenomics has now completed its transition period, which had more of a near-term impact on the business than anticipated, he argues, adding that the distractions are behind them and the sales force can now focus on driving new business, including a pipeline of new customers, growing existing accounts, and cross-selling into 100 Clarient IHC-only accounts.
09/11/17
BTIG
09/11/17
DOWNGRADE
BTIG
Neutral
NeoGenomics downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded NeoGenomics to Neutral saying shares are near his $11 price target and sees risk to Q3 revenues given exposure to Texas and Florida, and lack of near-term catalysts.
10/26/17
JANY
10/26/17
NO CHANGE
JANY
Buy
NeoGenomics should be bought on post-earnings weakness, says Janney Capital
Janney Capital analyst Paul Knight believes NeoGenomics can meet and beat estimates now that guidance has been lowered and he recommends buying the shares on any post-earnings weakness. He also noted that the company has already opened its' Switzerland laboratory, ahead of its guidance for a November opening. Knight keeps a Buy rating on NeoGenomics shares.
11/30/17
GABE
11/30/17
NO CHANGE
GABE
Buy
NeoGenomics named a best idea for 2018 at Gabelli
Gabelli analyst Sara Wojda named NeoGenomics a best idea for 2018 citing double-digit volume growth combined with double-digit reduction in cost per test, contined share gains in the core clinical services division, and expectations for stabilization in pricing for FISH tests. Wojda rates NeoGenomics a Buy with a $12 PMV.
AET Aetna
$172.06

-1.85 (-1.06%)

01/31/18
PIPR
01/31/18
NO CHANGE
Target $212
PIPR
Overweight
Piper sees buying opportunity in Aetna after yesterday's pullback
Piper Jaffray analyst Sarah James sees a buying opportunity in Aetna (AET) following yesterday's 3% pullback on the Amazon (AMZN), Berkshire (BRK.A) and JPMorgan (JPM) news. The company yesterday morning posted a solid earnings beat driven by strong cost trend management in the government and commercial businesses, James tells investors in a research note. She raised her price target for Aetna shares to $212 from $207 and keeps an Overweight rating on the name. CVS Health's (CVS) takeout offer now values the shares at $212, up from $207 previously, based on 0.8378 shares of CVS stock plus $145 per share in cash, James points out. The analyst sees a "win-win" setup for the stock based on the deal going through or the company remaining standalone.
01/31/18
RBCM
01/31/18
UPGRADE
Target $98
RBCM
Outperform
Express Scripts upgraded to Outperform at RBC Capital
As reported earlier, RBC Capital analyst George Hill upgraded Express Scripts (ESRX) to Outperform and raised his price target to $98 from $68. Hill cites the "recent sharp pullback on Amazon's (AMZN) healthcare entry" de-risking the stock, while also pointing to the trend of vertical integration as seen in the CVS (CVS)-Aetna (AET) deal. The analyst believes Express Scripts could also become an attractive M&A target as "one of the few remaining assets at scale".
01/31/18
FBCO
01/31/18
NO CHANGE
Target $208
FBCO
Neutral
Aetna price target raised to $208 from $200 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna to $208 from $200, citing on track operationally. However, the analyst is cautious on sustainability of tax benefit. He reiterates a Neutral rating on the shares.
02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.

TODAY'S FREE FLY STORIES

MCHP

Microchip

$82.29

-0.45 (-0.54%)

05:37
09/25/18
09/25
05:37
09/25/18
05:37
Initiation
Microchip initiated  »

Microchip initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.91

0.27 (0.58%)

05:37
09/25/18
09/25
05:37
09/25/18
05:37
Initiation
Intel initiated  »

Intel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AMD

AMD

$32.62

1.61 (5.19%)

05:37
09/25/18
09/25
05:37
09/25/18
05:37
Initiation
AMD initiated  »

AMD initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$95.01

0.45 (0.48%)

05:36
09/25/18
09/25
05:36
09/25/18
05:36
Initiation
Analog Devices initiated  »

Analog Devices initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HP

Helmerich & Payne

$67.61

0.34 (0.51%)

05:34
09/25/18
09/25
05:34
09/25/18
05:34
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$1.08

-0.11 (-9.24%)

, SNE

Sony

$56.86

-0.175 (-0.31%)

05:34
09/25/18
09/25
05:34
09/25/18
05:34
Hot Stocks
DHX Media concludes strategic review »

DHX Media (DHXM)…

DHXM

DHX Media

$1.08

-0.11 (-9.24%)

SNE

Sony

$56.86

-0.175 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ASC

Ardmore Shipping

$6.90

-0.05 (-0.72%)

05:33
09/25/18
09/25
05:33
09/25/18
05:33
Upgrade
Ardmore Shipping rating change  »

Ardmore Shipping upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

CENT

Central Garden & Pet

$38.28

-0.95 (-2.42%)

05:30
09/25/18
09/25
05:30
09/25/18
05:30
Initiation
Central Garden & Pet initiated  »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFIN

Donnelley Financial Solutions

$20.78

0.19 (0.92%)

05:27
09/25/18
09/25
05:27
09/25/18
05:27
Downgrade
Donnelley Financial Solutions rating change  »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$207.30

2.25 (1.10%)

05:26
09/25/18
09/25
05:26
09/25/18
05:26
Hot Stocks
Amgen announces approval for Blincyto in Japan »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 17

    Oct

  • 22

    Oct

  • 09

    Nov

SAIC

SAIC

$78.88

-0.59 (-0.74%)

, EGL

Engility

$35.14

-0.12 (-0.34%)

05:23
09/25/18
09/25
05:23
09/25/18
05:23
Upgrade
SAIC, Engility rating change  »

SAIC upgraded to Buy from…

SAIC

SAIC

$78.88

-0.59 (-0.74%)

EGL

Engility

$35.14

-0.12 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLR

Digital Realty

$115.95

-5.055 (-4.18%)

05:19
09/25/18
09/25
05:19
09/25/18
05:19
Syndicate
Digital Realty 8.5M share Secondary priced at $113.00 »

BofA/Merrill and Citi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 04

    Oct

  • 22

    Oct

  • 25

    Sep

SQ

Square

$86.06

0.75 (0.88%)

, FB

Facebook

$165.40

2.5 (1.53%)

05:18
09/25/18
09/25
05:18
09/25/18
05:18
Recommendations
Square, Facebook, Alphabet, Alphabet Class A, Amazon.com, Netflix analyst commentary  »

Square price target…

SQ

Square

$86.06

0.75 (0.88%)

FB

Facebook

$165.40

2.5 (1.53%)

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

NFLX

Netflix

$369.70

8.71 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 16

    Oct

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 03

    Mar

VIOT

Viomi Technology

$0.00

(0.00%)

05:18
09/25/18
09/25
05:18
09/25/18
05:18
Syndicate
Viomi Technology 11.4M share IPO priced at $9.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VCTR

Victory Capital

$9.50

0.45 (4.97%)

05:12
09/25/18
09/25
05:12
09/25/18
05:12
Upgrade
Victory Capital rating change  »

Victory Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

  • 10

    Oct

IRET

Investors Real Estate

$5.58

-0.03 (-0.53%)

05:11
09/25/18
09/25
05:11
09/25/18
05:11
Upgrade
Investors Real Estate rating change  »

Investors Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCCI

Heritage-Crystal Clean

$20.40

-0.15 (-0.73%)

05:10
09/25/18
09/25
05:10
09/25/18
05:10
Upgrade
Heritage-Crystal Clean rating change  »

Heritage-Crystal Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 01

    Oct

GHDX

Genomic Health

$70.84

1.65 (2.38%)

, LH

LabCorp

$169.54

-2.46 (-1.43%)

05:09
09/25/18
09/25
05:09
09/25/18
05:09
Recommendations
Genomic Health, LabCorp, Myriad Genetics, Natera, Quest Diagnostics analyst commentary  »

Piper sees early winners…

GHDX

Genomic Health

$70.84

1.65 (2.38%)

LH

LabCorp

$169.54

-2.46 (-1.43%)

MYGN

Myriad Genetics

$46.91

0.64 (1.38%)

NTRA

Natera

$23.83

-0.35 (-1.45%)

DGX

Quest Diagnostics

$107.61

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

  • 27

    Nov

WK

Workiva

$37.20

0.65 (1.78%)

05:08
09/25/18
09/25
05:08
09/25/18
05:08
Upgrade
Workiva rating change  »

Workiva upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CY

Cypress Semiconductor

$15.52

-0.45 (-2.82%)

05:07
09/25/18
09/25
05:07
09/25/18
05:07
Downgrade
Cypress Semiconductor rating change  »

Cypress Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLAR

Clarus Corporation

$10.45

-0.3 (-2.79%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
Clarus Corporation management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

AMSC

AMSC

$6.33

-0.265 (-4.02%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
AMSC management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

NNBR

NN, Inc.

$15.65

-0.05 (-0.32%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
NN, Inc. to host two day investor day »

Two day investor day to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 06

    Nov

LBTYA

Liberty Global

$28.37

-0.87 (-2.98%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
Liberty Global management to meet with Wolfe Research »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

TRU

TransUnion

$73.68

-0.62 (-0.83%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
TransUnion management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 21

    Oct

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.